{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:19:37Z","timestamp":1792279177036,"version":"4.4.0"},"reference-count":21,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23DK125760"],"award-info":[{"award-number":["K23DK125760"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. pediatr. gastroenterol. nutr."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Subcutaneous infliximab (IFX\u2010SC) offers a convenient alternative to intravenous infliximab (IFX\u2010IV) in inflammatory bowel disease (IBD) with more stable concentrations. Pediatric experience remains limited. We evaluated sustained clinical remission, pharmacokinetics, and safety\/tolerability after transition from IFX\u2010IV to IFX\u2010SC in children with IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective, single\u2010US\u2010center cohort of patients &lt;18 in clinical remission on maintenance IFX\u2010IV who transitioned to IFX\u2010SC (2022\u20132025). Demographic, clinical, and pharmacokinetic data were collected. The primary outcome was sustained clinical remission (defined: Harvey\u2013Bradshaw Index\u2009\u2264\u20094 or partial Mayo Score\u2009\u2264\u20092)\u2009\u2265\u200912 weeks (T1) after transition with no corticosteroids\/hospitalization\/surgery\/therapy\u2010cessation. Secondary outcomes were change in IFX concentrations, sustained remission at last follow\u2010up, and safety\/tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 36 prescribed, 22 (61%) initiated therapy (median age 15 [14\u201317] years; 73% Crohn's disease; 82% 120\u2009mg q2 weeks); age\u2010related insurance denial stopped 12\/14 from starting. Sustained clinical remission at T1 and last follow\u2010up (median 215 [162\u2013273] days) was achieved in 20\/22 (91%). Median IFX concentrations increased from 14.1 [9.7\u201322.4]\u2009\u00b5g\/mL (IV trough) to 29.5 [23.1\u201335.0]\u2009\u00b5g\/mL (SC steady\u2010state)\u2014a median 1.9 [1.5\u20132.9]\u2010fold increase in paired samples. Two with prior anti\u2010drug antibodies cleared them after switching. Adverse events were mild: injection\u2010site pain (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094, one discontinued), transient pruritus (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091), device misfire (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091), worsening psoriasiform dermatitis (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091, discontinued); no serious adverse events or anaphylaxis occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Transition to IFX\u2010SC maintained remission with an excellent safety profile. Steady\u2010state IFX\u2010SC levels approximated twice prior therapeutic IV troughs. Expanded labeling should be considered to ensure access reflects clinical necessity rather than administrative barriers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jpn3.70510","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T19:00:13Z","timestamp":1784746813000},"source":"Crossref","is-referenced-by-count":4,"title":["Subcutaneous infliximab in pediatric inflammatory bowel disease: Sustained remission, predictable pharmacokinetics, and real\u2010world US implementation"],"prefix":"10.1002","author":[{"given":"Patricia M.","family":"Hughes","sequence":"first","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition Mount Sinai Hospital New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanci","family":"Pittman","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition Mount Sinai Hospital New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Benkov","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition Mount Sinai Hospital New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Baez","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition Mount Sinai Hospital New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Festa","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition Mount Sinai Hospital New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana M.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition Mount Sinai Hospital New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouli","family":"Tung","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition Mount Sinai Hospital New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla C.","family":"Dubinsky","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition Mount Sinai Hospital New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6787-1164","authenticated-orcid":false,"given":"Elizabeth A.","family":"Spencer","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition Mount Sinai Hospital New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"5","key":"e_1_2_8_2_1","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1053\/j.gastro.2024.11.004","article-title":"Prevalence of pediatric inflammatory bowel disease in the United States: pooled estimates from three administrative claims data sources","volume":"168","author":"Kappelman MD","year":"2025","journal-title":"Gastroenterology"},{"issue":"1","key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.gastro.2021.04.063","article-title":"Approach to the management of recently diagnosed inflammatory bowel disease patients: a user's guide for adult and pediatric gastroenterologists","volume":"161","author":"Agrawal M","year":"2021","journal-title":"Gastroenterology"},{"issue":"9","key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/apt.18294","article-title":"Review article: novel therapies in inflammatory bowel disease \u2010 an update for clinicians","volume":"60","author":"Noor NM","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"e_1_2_8_5_1","article-title":"Tumor necrosis factor\u2010alpha antagonists for treatment of pediatric Crohn's disease","volume":"8","author":"Sep\u00falveda A","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cgh.2011.11.026","article-title":"Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis","volume":"10","author":"Hyams J","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","article-title":"Subcutaneous infliximab (CT\u2010P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials (LIBERTY)","volume":"167","author":"Hanauer SB","year":"2024","journal-title":"Gastroenterology"},{"issue":"9","key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/ecco-jcc\/jjae059","article-title":"Intravenous versus subcutaneous infliximab in inflammatory bowel disease: a systematic review and meta\u2010analysis","volume":"18","author":"Chetwood JD","year":"2024","journal-title":"J Crohn's Colitis"},{"issue":"11","key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1097\/MEG.0000000000002835","article-title":"Subcutaneous versus intravenous infliximab therapy\u2014a real\u2010world study: toward higher drug concentrations","volume":"36","author":"Ferreira AI","year":"2024","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"20","key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.3390\/jcm11206173","article-title":"Therapeutic drug monitoring of subcutaneous infliximab in inflammatory bowel disease\u2010understanding pharmacokinetics and exposure response relationships in a new era of subcutaneous biologics","volume":"11","author":"Little RD","year":"2022","journal-title":"J Clin Med"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","DOI":"10.1097\/MCG.0000000000002228","article-title":"Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: an individual participant data meta\u2010analysis","author":"Cummings F","year":"2025","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40261-022-01162-6","article-title":"Re\u2010routing infliximab therapy: subcutaneous infliximab opens a path towards greater convenience and clinical benefit","volume":"42","author":"Alten R","year":"2022","journal-title":"Clin Drug Invest"},{"issue":"13","key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.cgh.2025.04.028","article-title":"PErsistence and safety of subcutaneous infliximab 1 year after switch from intravenous route in IBD patients in REMission","volume":"23","author":"Mathieu N","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/ibd\/izab285","article-title":"Dashboard\u2010driven accelerated infliximab induction dosing increases infliximab durability and reduces immunogenicity","volume":"28","author":"Dubinsky MC","year":"2022","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/cpt.2148","article-title":"Real\u2010world infliximab pharmacokinetic study informs an electronic health record\u2010embedded dashboard to guide precision dosing in children with Crohn's disease","volume":"109","author":"Xiong Y","year":"2021","journal-title":"Clin Pharm Ther"},{"issue":"9","key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","article-title":"Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH study","volume":"21","author":"Buisson A","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MPG.0000000000003838","article-title":"Effectiveness of switching to subcutaneous infliximab in pediatric inflammatory bowel disease patients on intravenous maintenance therapy","volume":"77","author":"Gianolio L","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/FTD.0000000000000601","article-title":"Efficacy, pharmacokinetics, and immunogenicity is not affected by switching from infliximab originator to a biosimilar in pediatric patients with inflammatory bowel disease","volume":"41","author":"Hoeve K","year":"2019","journal-title":"Ther Drug Monit"},{"issue":"6","key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ibd.21493","article-title":"Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification","volume":"17","author":"Levine A","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"e_1_2_8_20_1","first-page":"467","article-title":"Infliximab in pediatric Crohn's disease patients","volume":"2","author":"Baldassano RN","year":"2006","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"1","key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/MPG.0000000000002141","article-title":"Use of biosimilars in pediatric inflammatory bowel disease: an updated position statement of the Pediatric IBD Porto Group of ESPGHAN","volume":"68","author":"Ridder L","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_8_22_1","volume-title":". European Commission Approves STELARA\u00ae (Ustekinumab) for the Treatment of Moderately to Severely Active Crohn's Disease in Paediatric Patients","author":"Johnson & Johnson","year":"2025"}],"container-title":["Journal of Pediatric Gastroenterology and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpn3.70510","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jpn3.70510","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpn3.70510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T19:00:16Z","timestamp":1784746816000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jpn3.70510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":21,"alternative-id":["10.1002\/jpn3.70510"],"URL":"https:\/\/doi.org\/10.1002\/jpn3.70510","archive":["Portico"],"relation":{},"ISSN":["0277-2116","1536-4801"],"issn-type":[{"value":"0277-2116","type":"print"},{"value":"1536-4801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"jpn3.70510"}}